Comparative Pharmacology
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO CEPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO TRI CYCLEN 21 versus ORTHO CEPT.
ORTHO TRI-CYCLEN 21 vs ORTHO-CEPT
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation; increases cervical mucus viscosity and alters endometrial receptivity.
Combination oral contraceptive containing desogestrel and ethinyl estradiol. Inhibits ovulation by suppressing gonadotropin secretion; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial development.
Prevention of pregnancy
Prevention of pregnancy
One tablet daily for 21 days, followed by 7 days of placebo, then repeat. Each tablet contains 0.180 mg norgestimate and 0.035 mg ethinyl estradiol (days 1–7), 0.215 mg/0.035 mg (days 8–14), and 0.250 mg/0.035 mg (days 15–21). Oral route.
One tablet (0.15 mg desogestrel / 0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (or 7 hormone-free days).
None Documented
None Documented
Norgestimate: ~24 hours (terminal); ethinyl estradiol: ~17 hours (terminal). Steady-state achieved within 5-7 days; clinical significance: missed doses may increase contraceptive failure risk.
Desogestrel: 23 hours (terminal), Etonogestrel active metabolite: 30 hours (terminal); clinical steady state after 7-10 days
Norgestimate: hydrolyzed to norelgestromin and norgestrel; metabolized by CYP3A4, CYP2C9, and CYP2C19. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation.
Ethinyl estradiol: primarily metabolized by CYP3A4; desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP2C19.
Renal: ~70% (metabolites, primarily glucuronide and sulfate conjugates of norgestimate and ethinyl estradiol); Fecal: ~30% (biliary elimination of unchanged drug and metabolites).
Renal: 50% (metabolites), Biliary/fecal: 40% (metabolites and unchanged drug), 10% unchanged in urine
Norgestimate: ~99% bound to albumin and SHBG; ethinyl estradiol: ~98% bound to albumin; norethindrone (active metabolite) binds with similar high affinity.
Desogestrel: 99% (SHBG), Etonogestrel: ~66% (albumin and SHBG); Ethinyl estradiol: 98% (albumin)
Norgestimate: Vd ~6-8 L/kg; ethinyl estradiol: Vd ~3-5 L/kg. Large Vd indicates extensive tissue distribution including breast, uterine, and hepatic tissues; clinical relevance: potential for drug interactions (e.g., enzyme inducers).
Desogestrel: 1.5 L/kg, Etonogestrel: 1.7 L/kg; indicates extensive tissue distribution
Oral: Norgestimate ~75% (first-pass metabolism limits bioavailability); ethinyl estradiol ~40-60% (substantial first-pass effect).
Desogestrel: 76% (oral, as prodrug converted to etonogestrel); Ethinyl estradiol: 45-50% (oral, first-pass metabolism)
No specific dose adjustment is provided in manufacturer labeling; use with caution in patients with renal impairment. GFR-based adjustments are not established.
No dose adjustment required for mild to moderate renal impairment. Limited data in severe renal impairment; use is not recommended due to potential fluid/electrolyte disturbances.
Contraindicated in patients with hepatic disease or hepatocellular carcinoma. Child-Pugh class B or C: contraindicated. Child-Pugh class A: use with caution, no specific dose adjustment defined.
Contraindicated in Child-Pugh class B or C (severe hepatic impairment) and in acute liver disease. Caution in Child-Pugh class A; monitor liver function; consider alternative method.
Safety and efficacy established in postmenarchal females; dosing is same as adult: one tablet daily for 21 days. Weight-based dosing not applicable.
Post-menarchal adolescents: Same dosing regimen as adults (1 tablet daily). Not indicated for use before menarche.
Not indicated for use in postmenopausal women. No specific considerations available.
Not indicated for use in postmenopausal women. Contraceptive efficacy not applicable; estrogen-containing combination contraceptives are generally not recommended in women over 35 who smoke or have other cardiovascular risk factors.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives (COCs). Women over 35 who smoke should not use COCs.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Women over 35 who smoke should not use this product.
["Thrombotic disorders (e.g., thrombophlebitis, pulmonary embolism, stroke, myocardial infarction)","Hepatic disease (including hepatic adenoma or carcinoma)","Hypertension","Gallbladder disease","Carbohydrate/lipid metabolism disturbances","Headache (including migraine with focal symptoms)","Uterine bleeding irregularities"]
["Thrombotic disorders (venous thromboembolism, arterial thromboembolism)","Cerebrovascular disease","Cigarette smoking in women >35 years","Hypertension","Gallbladder disease","Hepatic neoplasia","Bleeding irregularities"]
["Known or suspected pregnancy","Current or history of thromboembolic disorders (e.g., DVT, PE)","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Hepatic adenoma or carcinoma, or active liver disease","Hypersensitivity to any component","Smoking in women over 35 years","Uncontrolled hypertension","Diabetes with vascular involvement","Migraine with aura if >35 years","Major surgery with prolonged immobilization"]
["High risk of arterial or venous thrombotic events","Current or history of breast cancer or other estrogen-sensitive cancer","Hepatic adenoma or carcinoma","Undiagnosed abnormal uterine bleeding","Pregnancy","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No specific food restrictions; however, grapefruit juice may increase estrogen levels (minor interaction). Avoid St. John's wort, which can reduce contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, but effect is minor; typical dietary intake does not require restriction. High-fat meals may delay absorption but no dose adjustment needed. Maintain consistent dietary patterns for peak concentration predictability.
First trimester: Risk of congenital anomalies (limb defects, neural tube defects) based on case reports; overall risk low. Second/third trimester: Possible increased risk of intrauterine growth restriction and preterm birth. Postnatal: Potential for jaundice and transient hormonal effects in neonates.
Contraindicated during pregnancy due to risk of fetal harm. First trimester exposure linked to cardiovascular defects and limb reduction defects. Second and third trimester exposure associated with fetal genital abnormalities and potential long-term effects from progestin activity.
Contraindicated in breastfeeding due to estrogens reducing milk production and quality. Limited data; M/P ratio not established. Alternative methods preferred.
Small amounts of desogestrel and ethinyl estradiol excreted in breast milk; M/P ratio not well established. Use not recommended during breastfeeding as it may reduce milk production and quality. Alternative contraception advised.
No dose adjustments needed as drug is contraindicated during pregnancy. Discontinue immediately upon confirmed pregnancy; pharmacokinetic changes not applicable.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist as use is not recommended.
Category C
Category C
ORTHO TRI-CYCLEN 21 contains norgestimate and ethinyl estradiol; it is a triphasic oral contraceptive with varying hormone doses across 21 active pills. Its progestin component has low androgenicity, making it suitable for patients with acne or hirsutism. Monitor for thromboembolic risk, especially in smokers over 35. Missed pill management: if one active pill is missed, take it as soon as remembered and continue; if two or more are missed, use backup contraception and consider emergency contraception.
ORTHO-CEPT (desogestrel/ethinyl estradiol) is a monophasic oral contraceptive. Counsel patients that missed pills increase risk of breakthrough bleeding and pregnancy; refer to package insert for missed dose instructions. Consider reduced efficacy with hepatic enzyme inducers (e.g., rifampin, phenytoin). Caution in patients with migraine with aura due to increased stroke risk. May cause chloasma; advise sun protection.
Take one pill daily at the same time for 21 days, then 7 placebo pills.Use backup contraception (e.g., condoms) for the first 7 days of initial use.Common side effects: nausea, breast tenderness, breakthrough bleeding; these often improve after 2-3 cycles.Report signs of blood clots: leg pain/swelling, chest pain, sudden shortness of breath, severe headache.Smoking increases blood clot risk; do not smoke while using this medication.If severe vomiting or diarrhea occurs within 4 hours after taking a pill, consider it missed and follow missed pill instructions.
Take one pill daily at the same time each day for 21 days, then 7 placebo pills.If you vomit or have severe diarrhea within 4 hours of taking a pill, use backup contraception for 7 days.Do not smoke while taking this medication due to increased risk of blood clots.Inform your healthcare provider if you develop severe headache, chest pain, shortness of breath, or leg swelling.Use additional contraception if you miss two or more active pills in a row.